<DOC>
<DOCNO>EP-0642349</DOCNO> 
<TEXT>
<INVENTION-TITLE>
USE OF URODILATIN IN PULMONARY AND BRONCHIAL DISEASES
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3822	A61P1100	A61P1100	A61K3822	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61P	A61P	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K38	A61P11	A61P11	A61K38	</CLASSIFICATIONS-FOURTH>
<APPLICANTS>
<APPLICANT-NAME>
HAEMOPEP PHARMA GMBH
</APPLICANT-NAME>
<APPLICANT-NAME>
HAEMOPEP PHARMA GMBH
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
FLUEGE THOMAS
</INVENTOR-NAME>
<INVENTOR-NAME>
FORSSMANN WOLF-GEORG
</INVENTOR-NAME>
<INVENTOR-NAME>
FLUEGE, THOMAS
</INVENTOR-NAME>
<INVENTOR-NAME>
FORSSMANN, WOLF-GEORG
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Use of a pharmaceutical composition containing urodilatin
as the active ingredient and optionally pharmaceutically

usual diluents, vehicles, fillers or auxiliary agents for
the preparation of a medicament for the treatment of lung

and/or bronchial diseases.
The use according to claim 1 for the preparation of a
medicament for the treatment of obstructive respiratory

tract diseases.
The use according to claim 1 or 2, characterized in that a
parenterally, intravenously or inhalatorily, administer-able

medicament is prepared.
The use according to any of claims 1 to 3, characterized
in that a unit dose of the medicament corresponds to from

5 ng to 1000 µg of urodilatin/kg of body weight.
The use according to claim 4, characterized in that a unit
dose of the medicament corresponds to from 10 ng to 100 µg

of urodilatin/kg of body weight.
</CLAIMS>
</TEXT>
</DOC>
